Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | GNPAT | O15228 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisorcic SCHEMBL2109664 | 1.00 | FOLH1 (0.64) | FOLH1SMN1; SMN2KDM4EMAPTTHRB | |
| Bisorcic SCHEMBL16238411 | 1.00 | FOLH1 (0.64) | FOLH1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL1200060 | 0.94 | FOLH1 (0.71) | FOLH1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL2735591 | 0.94 | FOLH1 (0.71) | FOLH1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL16393150 | 0.94 | FOLH1 (0.71) | FOLH1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL12439670 | 0.88 | SMN1; SMN2 (0.55) | FOLH1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL14942518 | 0.88 | FOLH1 (0.64) | FOLH1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL25550095 | 0.88 | FOLH1 (0.64) | FOLH1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL468875 | 0.87 | FOLH1 (0.51) | FOLH1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL468877 | 0.87 | FOLH1 (0.51) | FOLH1SMN1; SMN2KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230375534-A1 | MEANS AND METHODS TO DIAGNOSE GUT FLORA DYSBIOSIS AND INFLAMMATION | VIB VZW (BE) | 2023-11-23 | — | — | US | claimed |
| EP-3546940-B1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON INC (US) | 2021-02-17 | — | — | EP | claimed |
| US-10865183-B2 | Compounds, reagents, and uses thereof | METABOLON, INC. (US) | 2020-12-15 | — | — | US | claimed |
| EP-3688470-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | Metabolon, Inc. (US) | 2020-08-05 | — | — | EP | claimed |
| US-20200231541-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | METABOLON, INC. | 2020-07-23 | — | — | US | claimed |
| US-20200103417-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. | 2020-04-02 | — | — | US | claimed |
| EP-3546940-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2019-10-02 | — | — | EP | claimed |
| EP-3491004-A1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | Metabolon, Inc. (US) | 2019-06-05 | — | — | EP | claimed |
| US-20190152907-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | METABOLON, INC. | 2019-05-23 | — | — | US | claimed |
| WO-2019067699-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | METABOLON, INC. (US) | 2019-04-04 | — | — | WO | claimed |
| US-20160116486-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. | 2016-04-28 | — | — | US | claimed |
| EP-2997366-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2016-03-23 | — | — | EP | claimed |
| WO-2016025429-A1 | PRECISE ESTIMATION OF GLOMERULAR FILTRATION RATE FROM MULTIPLE BIOMARKERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-18 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014186311-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. (US) | 2014-11-20 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865183-B2 | Compounds, reagents, and uses thereof | REN, ATP6V1B1, PKD1 | FOLH1 571/4885SMN1; SMN2 4241/4885KDM4E 3199/4885 |
| US-20200231541-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | REN, ATP6V1B1, PKD1 | FOLH1 967/4885SMN1; SMN2 3868/4885KDM4E 2469/4885 |
| US-20190152907-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | REN, ATP6V1B1, PKD1 | FOLH1 571/4885SMN1; SMN2 4241/4885KDM4E 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.